Influenza
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- An acute viral infection of the respiratory tract, occurring in isolated cases, in epidemics, or in pandemics; it is caused by serologically different strains of viruses (influenzaviruses) designated A, B, and C, has a 3-day incubation period, and usually lasts for 3 to 10 days. It is marked by inflammation of the nasal mucosa, pharynx, and conjunctiva; headache; myalgia; often fever, chills, and prostration; and occasionally involvement of the myocardium or central nervous system.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Influenza
- Therapeutic area
- Infectious Disease
- influenza
- Influenza with other manifestations
- flu
- influenza infection
- orthomyxoviridae caused disease or disorder
- orthomyxoviridae disease or disorder
- orthomyxoviridae infectious disease
- Disease mechanisms
- Acquired
- Severity
- Mild
- Infectious Disease
- Pulmonology
- MONDO ID
- MONDO:0005812
- Parent condition
- MONDO:0024352
Related records
Broader conditions (11)
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
- Primary viral infectious disease
- Respiratory system disorder
- Respiratory tract infectious disorder
- Viral infectious disease
- Viral respiratory tract infection
Narrower conditions (2)
- Avian influenza
- Swine influenza
Trials (2,156)
- "COhort Study on A/H1N1 FLU During PREGnancy"
- "Quidel Reader Influenza A + B Test 510(k) and CLIA Waiver Field Study"
- 2-week dc of MTX and Influenza Vaccination in RA
- 2009 H1N1 Pandemic and Seasonal Influenza in SCI/D: Infection Control Strategies
- 2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women
- 2010/2011 Trivalent Influenza Vaccination
- 2013/2017 H7N9 Prime-Boost Interval
- 2017 A/H7N9 IIV Revaccination
- 4 Pillars Toolkit for Adolescent Vaccination
- A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age
- A Clinical Study of Treating Influenza With Liugan Shuangjie Heji
- A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
- A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age
- A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
- A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection
- A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses
- A Clinical Trial of A Quadrivalent Influenza Vaccine
- A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years
- A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years
Approved drugs (21)
- Acetaminophen
- Amantadine hydrochloride
- Baloxavir marboxil
- Ibuprofen
- Influenza A virus hemagglutinin
- Influenza A virus, inactivated hemagglutinin
- Influenza A virus, inactivated neuraminidase
- Influenza A virus, inactivated whole virion
- Influenza A virus, live attenuated
- Influenza A virus, split virion
- Influenza B virus hemagglutinin
- Influenza B virus, inactivated hemagglutinin
- Influenza B virus, inactivated neuraminidase
- Influenza B virus, live attenuated
- Influenza B virus, split virion
- Oseltamivir phosphate
- Peramivir
- Pseudoephedrine hydrochloride
- Rimantadine hydrochloride
- Zanamivir
Drugs in development (93)
- Acetylcysteine Phase 3
- AD26.RSV.PREF Phase 3
- Aluminum hydroxide Phase 1
- Amantadine Phase 2
- Amoxicillin Phase 3
- Anakinra Phase 3
- Apremilast Phase 3
- Ascorbic acid Phase 3
- Aspirin Phase 3
- Atorvastatin Phase 2
- Baicalein Phase 2
- Baloxavir Phase 2
- Baricitinib Phase 3
- Bermekimab Phase 3
- Ceftaroline Phase 3
- Ceftriaxone Phase 3
- Celecoxib Phase 3
- Chloroquine Phase 2
- Chlorpheniramine Phase 3
- Cholecalciferol Phase 3
Other linked drugs (2)
- Ingavirin
- Rimantadine